RecruitingNot ApplicableNCT06528184

Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings


Sponsor

National Healthcare Group Polyclinics

Enrollment

650 participants

Start Date

Aug 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone. The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.


Eligibility

Sex: FEMALEMin Age: 30 YearsMax Age: 69 Years

Inclusion Criteria5

  • years old female Singapore citizens
  • Due for cervical cancer screening
  • Engaged in sexual intercourse before
  • Able to give informed consent
  • Able to read and communicate in English, Chinese or Malay

Exclusion Criteria3

  • Virgo intacta
  • Pregnancy
  • History of cervical cancer, precancerous cervical lesions and total hysterectomy

Interventions

DIAGNOSTIC_TESTSelf-sampled HPV DNA testing

Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)

DIAGNOSTIC_TESTClinician-sampled HPV DNA test

Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)


Locations(1)

National Healthcare Group Polyclinics

Singapore, Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06528184


Related Trials